Loading patent…
AssigneeThe Trustees of the University of Pennsylvania
InventorsRonald J BUCKANOVICH, George COUKOS, Andrea FACCIABENE
Estimating the term…
The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of ETRB, ET-1, ICAM-1, or another protein found herein to play a role in homing of T cells to a solid tumor. The present invention also provides methods of prognosticating a solid tumor in a subject, comprising the step of measuring an expression level of a protein found herein to play a role in homing of T cells to a solid tumor, or a nucleotide molecule encoding same.
A method of treating or of enhancing an efficacy of an immunotherapy for a solid tumor in a subject, comprising the step of contacting said subject with a compound or a composition that reduces an activity of or expression of an Endothelin B receptor (ETRB).
-12. (canceled)
A method of treating or of enhancing an efficacy of an immunotherapy for a solid tumor in a subject, comprising the step of contacting said subject with a compound or composition that reduces an activity of or expression of a protein selected from Musashi 2, delta-like 1, Hairy/Enhancer of Split 1, MEG3, SEC61G, KIAA1609, ACTR6, clone LNG00414, ATP9A, IMAGE:23539, NCOA1, WIT1, PAPSS2, ALDOA, ZNF423, ENPP2, HSU79266, KIAA0146, IMAGE:1902075, EMX2, MYBL1, IMAGE:1660792, IMAGE:191524, IMAGE:2365035, TAF3, SLC1A4, and SGCB.
-20. (canceled)
A method of treating or of enhancing an efficacy of an immunotherapy for a solid tumor in a subject, comprising the step of contacting said subject with a compound or a composition that increases an activity of or expression of a protein selected from a CASP8 and FADD-like apoptosis regulator (CFLAR) protein;
(canceled)
(canceled)
A method of enhancing an efficacy of an immunotherapy for a solid tumor in a subject, comprising the step of contacting said subject with a compound or a composition that reduces an expression or activity of an endothelin-1 (ET-1) protein or that reduces interaction between an Endothelin B receptor (ETRB) and an endothelin-1 (ET-1), thereby enhancing an efficacy of an immunotherapy for a solid tumor in a subject.
-31. (canceled)
A method of enhancing an efficacy of an immunotherapy for a solid tumor in a subject, comprising the step of contacting said subject with a compound or a composition that increases an expression or an activity of an intercellular adhesion molecule 1 (ICAM-1 protein), thereby enhancing an efficacy of an immunotherapy for a solid tumor in a subject.
Dependencies are inferred from the claim text.